Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
09:50am, Tuesday, 23'rd Mar 2021
Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
Glaukos Announces Participation in Oppenheimer Healthcare Conference
07:00am, Tuesday, 02'nd Mar 2021
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d
Glaukos' (GKOS) CEO Tom Burns on Q4 2020 Results - Earnings Call Transcript
10:34am, Sunday, 28'th Feb 2021
Glaukos' (GKOS) CEO Tom Burns on Q4 2020 Results - Earnings Call Transcript
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
10:37am, Friday, 26'th Feb 2021
Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
Glaukos' iLink Therapy Meets Primary Endpoint In Late-Stage Vision Disorder Study
08:48am, Friday, 26'th Feb 2021
Glaukos Corp (NYSE: GKOS) has announced topline data from the U.S. Phase 3 trial evaluating its corneal cross-linking iLink therapy to treat keratoconus. Keratoconus is characterized by cone-shape
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
06:58pm, Thursday, 25'th Feb 2021
Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Glaukos: Q4 Earnings Insights
05:11pm, Thursday, 25'th Feb 2021
Shares of Glaukos (NYSE:GKOS) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.02), which beat the estima
Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
01:42pm, Thursday, 18'th Feb 2021
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25
07:00am, Thursday, 04'th Feb 2021
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d
Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study
07:00am, Wednesday, 13'th Jan 2021
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d
Iridex To Benefit From New Revolutionary Glaucoma Treatment
09:28am, Monday, 11'th Jan 2021
Iridex To Benefit From New Revolutionary Glaucoma Treatment
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
07:00am, Wednesday, 23'rd Dec 2020
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d
Glaukos Announces Participation in Upcoming Investor Conferences
04:15pm, Wednesday, 11'th Nov 2020
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d
Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2020 Results - Earnings Call Transcript
11:19am, Sunday, 08'th Nov 2020
Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2020 Results - Earnings Call Transcript
Stock Traders Buy Large Volume of Glaukos Call Options (NYSE:GKOS)
01:24am, Saturday, 10'th Oct 2020
Glaukos Corp (NYSE:GKOS) was the recipient of some unusual options trading on Friday. Stock traders acquired 3,067 call options on the stock. This is an increase of approximately 1,354% compared to th
